A cobalt-based strategy for tumour targeting of EGFR-inhibitors

The development of receptor tyrosine-kinase inhibitors (TKIs) in recent decades was a major step forward in cancer treatment. However, despite their clinical efficacy, therapy with TKIs is limited by strong side effects (such as skin rash) and development of resistance. New approaches are required
to overcome these drawbacks. Complexing the TK Inhibitor with Cobalt (Co3+) inactivates the inhibitor until it is released under the hypoxic conditions in the target tumour tissue. This approach promises effective treatment with considerably limited side effects. These complexes can be used as an alternative to existing
Epidermal Growth Factor Receptor (EGFR) Inhibitors, and were effective in tumour cells that have become resistant to conventional Treatments due to EGFR mutations like T790M.

Further information: PDF

Wissenstransferzentrum Ost (WTZ Ost)
Phone: +43 1 401 60 25 202

Contact
Dr. Michael Hoschitz

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.